Replies to post #170118 on Biotech Values

[DewDiligence]

B-I starts two phase-3 trials of Pradaxa in new indications: one in NVAF patients who received a stent, and one in secondary prevention of embolic stroke:

http://finance.yahoo.com/news/boehringer-ingelheim-planning-initiate-two-130000990.html